← Leaderboards
William L Klein
Northwestern University
$7,573,106
Attributed
$11,851,970
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,851,970 · 10
By mechanism
R01$6,692,410 · 4
RF1$2,909,025 · 1
R21$1,266,516 · 3
R56$761,827 · 1
R41$222,192 · 1
Top collaborators
- Pembe Hande Ozdinler2 shared
- Richard B Silverman2 shared
- John F Disterhoft1 shared
- Neil L Kelleher1 shared
- Steven Matthew Patrie1 shared
Most similar at Northwestern University
Same institution · by research overlap
- Richard B Silverman$24,563,202
- Han-Xiang Deng$10,076,503
- Evangelos Kiskinis$8,798,472
- Robert G Kalb$17,119,729
- Robert J Vassar$28,822,218
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainSynapsesNeuronsDementiaPathologyProteinsBaseLigandsMemoryNeuropathologyAnimal ModelMemory LossMolecularNeurotoxinsAffectBinding (Molecular Function)Abeta OligomerPharmaceutical PreparationsTau ProteinsSamplingEventPathogenesis
Grant awards (23)
Investigations of the protein aggregation inhibitor NU-9 and its derivatives: mode of action and impact on Alzheimerâs disease and related dementias$1,401,127
R01 · FY2025 · AG
Investigations of the protein aggregation inhibitor NU-9 and its derivatives: mode of action and impact on Alzheimerâs disease and related dementias$1,536,774
R01 · FY2024 · AG
Defining native proteoform landscape for amyloid-beta in Alzheimers disease$2,909,025
RF1 · FY2019 · AG
Physiological role of naturally-occuring amyloid beta oligomers$192,910
R21 · FY2019 · AG · contact PI
Sporadic Alzheimer's Disease modeled with diabetes and high cholesterol in rabbit$761,827
R56 · FY2018 · AG · contact PI
Physiological role of naturally-occuring amyloid beta oligomers$222,757
R21 · FY2018 · AG · contact PI
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.$222,192
R41 · FY2016 · AG · contact PI
A novel, nanoparticle-based molecular MRI probe for early Alzheimer's diagnostics$187,331
R21 · FY2015 · AG · contact PI
A novel, nanoparticle-based molecular MRI probe for early Alzheimer's diagnostics$231,750
R21 · FY2014 · AG · contact PI
Alzheimer's Drug Discovery Using Unique Nanotechnology Platform$184,393
R21 · FY2013 · AG · contact PI
Alzheimer's Drug Discovery Using Unique Nanotechnology Platform$247,375
R21 · FY2012 · AG · contact PI
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology$306,455
R01 · FY2010 · AG · contact PI
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology$309,550
R01 · FY2009 · AG · contact PI
ADDLs, synapses & the molecular etiology of Alzheimer's disease$303,359
R01 · FY2009 · AG · contact PI
Abeta oligomers (ADDLs) in Alzheimer's Disease pathology$309,550
R01 · FY2008 · AG · contact PI
ADDLs, synapses & the molecular etiology of Alzheimer's disease$303,359
R01 · FY2008 · AG · contact PI
ADDLs, synapses & the molecular etiology of Alzheimer's disease$309,550
R01 · FY2007 · AG · contact PI
Abeta oligomers (ADDLs)in Alzheimers Disease pathology$346,066
R01 · FY2005 · AG
Abeta oligomers (ADDLs)in Alzheimers Disease pathology$346,227
R01 · FY2004 · AG
Abeta oligomers (ADDLs) in Alzheimers Disease pathology$330,509
R01 · FY2003 · AG
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS$292,257
R01 · FY2003 · AG
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS$293,103
R01 · FY2002 · AG
NEUROLOGICAL DEFICITS DUE TO TOXIC A BETA OLIGOMERS$304,524
R01 · FY2001 · AG